Abstract: The PathfinderTG biomarker panel is useful in the evaluation of pancreatic cysts that have clinical features suspicious for malignancy, but its utility in classifying fine-needle aspiration biopsies from small pancreatic cystic lesions is yet to be proven. We used morphology to classify 20 pancreatic cyst cytology aspirates, all of which met radiographic criteria for close observation. Cases were cytologically classified as consistent with pseudocyst, serous cystadenoma, or mucinous neoplasm with lowgrade, intermediate-grade, or high-grade dysplasia and analyzed for carcinoembryonic antigen. Redpath Integrated Pathology Inc. rendered diagnoses of nonmucinous (reactive/indolent or serous) or mucinous (low-risk or at risk) cyst on the basis of results of the PathfinderTG panel (KRAS mutations, DNA content, and loss of heterozygosity at microsatellites linked to tumor suppressor genes). Cytologic and commercial laboratory diagnoses were concordant in only 7 (35%) cases. Seven cysts classified as mucinous with low-grade dysplasia by cytology were interpreted as nonmucinous on the basis of the PathfinderTG panel, 2 of which were resected mucinous cysts. Two pancreatitis-related pseudocysts were misdiagnosed as low-risk mucinous cysts; 1 mucinous cyst with low-grade dysplasia was considered at risk for neoplastic progression using the PathfinderTG panel. Only 1 cyst misclassified as pseudocyst by cytology, but low-risk mucinous cyst by molecular analysis, proved to be a mucinous cystic neoplasm with low-grade dysplasia after surgical resection. We conclude that the PathfinderTG panel may aid the classification of pancreatic lesions, but is often inaccurate and should not replace cytologic evaluation of these lesions.
A dvances in cross-sectional imaging techniques and increased use of these modalities have enhanced detection of pancreatic cystic lesions, many of which are small and at low risk for aggressive behavior. 1 Accurate classification of pancreatic cysts is clinically important, as nonmucinous cysts have essentially no malignant potential, whereas mucinous cysts may progress to invasive adenocarcinoma in some cases. Indications for surgical removal of mucinous cysts include: (1) involvement of the main pancreatic duct; (2) mural nodules; (3) size >3 cm; and (4) high-grade dysplastic or malignant cytologic features. 2 Mucinous lesions that lack these features are managed more conservatively as their cancer risk is considered to be low. Small (< 3 cm), uncomplicated cysts with low-grade cytology are increasingly managed with surveillance, rather than surgery, and now account for most pancreatic mucinous cysts that come to clinical attention. 3 The initial evaluation of pancreatic cystic lesions includes high-resolution computed tomography scanning and endoscopic ultrasound in combination with fineneedle aspiration biopsy for cytologic and biochemical assessment of cyst fluid. Limitations to cytologic assessment include the scant nature of many specimens, contamination of aspirates by epithelium from the upper gastrointestinal tract, and presence of reactive epithelial cell atypia that mimics, or masks, neoplasia. Furthermore, the distinction of low-grade from high-grade dysplasia in mucinous epithelium can be challenging. 4 Thus, ancillary techniques that aid cytologic evaluation of pancreatic cyst aspirates are needed.
Pancreatic cysts show biochemical and physical properties that may be exploited in order to aid their cytologic evaluation. Mucinous cysts have viscous contents with elevated tumor marker levels [eg, carcinoembryonic antigen (CEA), CA19-9, and CA125], whereas pseudocysts contain cloudy fluid with high pancreatic enzyme levels, and serous cysts lack glycoprotein elevations. Unfortunately, fluid viscosity, tumor markers, and enzyme concentrations lack sufficient sensitivity and specificity to be entirely relied upon for classification of pancreatic cysts and, thus, molecular analyses have recently emerged as promising adjuncts to their evaluation. Sloughed epithelial cells contain DNA that can be analyzed for molecular abnormalities. Most mucinous cysts contain denuded epithelial cells that harbor KRAS mutations. Progressively severe dysplasia is accompanied by loss of heterozygosity (LOH) at microsatellites linked to tumor suppressor genes. 5 These features have been incorporated into biomarker panels promoted by commercial laboratories, many of which solicit samples directly from gastroenterologists, thereby bypassing pathologic interpretation of the material. One such laboratory, Redpath Integrated Pathology Inc. (Pittsburgh, PA), promotes the PathfinderTG panel. This assay reportedly distinguishes between nonmucinous and mucinous pancreatic cysts and predicts the biological behavior of the latter, but its utility has not been independently validated. The purpose of this study was to evaluate the relationship between results of the PathfinderTG panel and cytologic evaluation of endoscopic ultrasound-guided fine-needle aspiration biopsy material from incidentally discovered pancreatic cysts. We evaluated 20 pancreatic cyst aspirates from 18 patients who underwent endoscopic ultrasound and fineneedle aspiration biopsy. An aliquot of each cyst was submitted to our own laboratory for cytologic assessment, and a separate aliquot was sent to Redpath Integrated Pathology Inc., where it was analyzed for KRAS mutations, LOH, and DNA content using the PathfinderTG assay. The results of these 2 methodologies were assessed in light of the clinical situation and compared with findings present in surgical resection specimens, when available.
MATERIALS AND METHODS

Clinical Features
We prospectively identified 18 patients with pancreatic cystic lesions that were incidentally discovered during radiologic studies performed for indications unrelated to the pancreas. All of the patients were subsequently evaluated by endoscopic ultrasound-guided fine-needle aspiration biopsy at the Jay Monahan Center for Gastrointestinal Health at Weill Cornell Medical College (New York, NY). A sample of the cyst fluid from each case was submitted to the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College for cytologic evaluation. A separate aliquot from the same sample was simultaneously sent to Redpath Integrated Pathology Inc. (Pittsburgh, PA) for molecular analysis, as described below. Patient information, including available follow-up information, was obtained from the electronic hospital medical record system. This study was approved by the Institutional Review Board of Weill Cornell Medical College.
Cytologic Assessment of Cyst Fluid
Direct smears and ThinPrep slides were prepared from fine-needle aspiration biopsy samples. Air-dried smears were stained with Diff-Quik, and both alcoholfixed smears and ThinPrep slides were stained with the Papanicolaou stain using standard techniques. Glass slides (mean, 7; range, 2 to 11) from each case were reviewed by 2 cytopathologists blinded to the radiographic findings, the original cytologic interpretation, and the results of all ancillary studies. Cystic lesions were classified as (1) non-neoplastic, consistent with pancreatic pseudocyst; (2) serous cystadenoma; (3) mucinous cyst; and (4) pancreatic (neuro)endocrine tumor, according to the following accepted criteria. 6 A diagnosis of pancreatic pseudocyst was favored when the specimen contained nonmucinous, proteinaceous material, and macrophages without mucinous epithelium. Hypocellular specimens composed of clear serous fluid and scant cuboidal cells arranged singly or in loose clusters were classified as serous cystadenomas. A diagnosis of mucinous cyst was rendered when aspirates contained cuboidal or columnar mucinous glandular cells and background mucin. Mucinous cysts were subclassified on the basis of the degree of cytologic atypia present in lesional cells. [7] [8] [9] Cysts with low-grade dysplasia were defined as those that contained organized clusters of cells with a low nuclear to cytoplasmic ratio, evenly dispersed chromatin, and inconspicuous nucleoli. Aspirates that contained crowded clusters of cells with nuclear pleomorphism, loss of polarity, and nucleolar prominence were considered to show high-grade dysplasia. Dysplastic cytologic features intermediate between those of low-grade and high-grade dysplasia were deemed intermediate grade. Smears composed of a monotonous population of small, polygonal cells with stippled chromatin and inconspicuous nucleoli were classified as pancreatic (neuro)endocrine tumor. Histologic sections obtained from subsequent surgical resection specimens were reviewed when patients were surgically treated.
Four specimens had adequate material to assess for CEA concentration. This evaluation was carried out using the ADVIA Centaur 2-site sandwich immunoassay and direct chemiluminescence (Bayer Diagnostics, Tarrytown, NY). A cutoff value of 3.0 ng/mL was used to establish CEA elevation as determined by Bayer Diagnostics.
Molecular Analysis of Cyst Fluid
Cyst fluid samples were submitted to Redpath Integrated Pathology Inc. between 2005 and 2010, where they were evaluated using the PathfinderTG assay. 10 This panel includes DNA quantification (amount and quality), evaluation for KRAS activating point mutations (codon 12 of exon 1), and assessment of allelic loss of tumor suppressor gene-linked microsatellite markers. The latter analysis was performed on extracted DNA subjected to polymerase chain reaction using a broad panel of microsatellite markers [9p21 (MTS-1), 17p (TP53), 18q (DPC4), 9q22 (PTCH), 1p36 (RIZ), 3p25-3p26 (VHL), 5q23 (APC), 10q23 (PTEN)] that have been implicated in pancreatic carcinogenesis. Products from each polymerase chain reaction were analyzed by capillary electrophoresis on an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA). Informative samples with a polymorphic allelic imbalance ratio <0.5 or >2.0 were considered to show allelic imbalance and LOH. A buccal brushing sample was used as a normal control. The sequence of mutation acquisition was calculated using a clonal expansion model, and the results were summarized in a report provided to the submitting gastroenterologist. Each report included an interpretation of the findings and recommended therapy on the basis of an algorithm created by Redpath Integrated Pathology Inc., as detailed in Table 1 . Although CEA levels were not evaluated at Redpath Integrated Pathology Inc., these values were incorporated into the algorithm if provided by the submitting institution. Pancreatic cysts were categorized as mucinous or nonmucinous on the basis of the presence or absence of KRAS mutations, respectively. Cysts without KRAS mutations and no other mutations were considered reactive or indolent, and those with LOH limited to chromosome 3p were classified as serous cystadenomas. Cysts with a KRAS mutation, LOH at any other locus, low DNA content, and low CEA concentration were classified as low-risk mucinous cysts and qualified with a comment that the lesion may remain stable, progress with further accumulation of mutations, or regress. The recommended clinical follow-up for such a lesion was a nonoperative course with interval radiologic reevaluation and possible repeat aspiration. Cysts that harbored a KRAS mutation and either LOH at 2 loci, moderate to high DNA content, or an elevated CEA level (as determined by the submitting institution) were classified as mucinous cysts at risk for neoplastic progression. 11 Correlation with clinical and radiographic features was suggested, but no specific follow-up recommendations were made.
RESULTS
Clinical Features
Twenty cysts from 18 patients comprised the study group. Most patients were women (male/female ratio, 1/5) with a mean age of 65 years (range, 35 to 79 y). Two cysts were multilocular and 18 were unilocular. Most cysts were small (mean, 25 mm; median, 19 mm; range, 5 to 50 mm) and evenly distributed in the pancreatic body, head, and tail. One cyst was located in the uncinate process. One patient with 3 metachronous cysts had 2 lesions in the tail and 1 in the body of the pancreas.
Pathologic Features
Review of cytologic smears yielded diagnoses of a nonmucinous cyst in 6 cases and mucinous cyst in 14 cases, including 1 patient with 3 metachronous cysts. All 3 cysts from that patient were sampled and interpreted to be mucinous in nature. Four nonmucinous cysts were considered to be non-neoplastic and likely pseudocysts, 1 was classified as a serous cystadenoma, and 1 was diagnosed as a (neuro)endocrine tumor ( Fig. 1 ). Cytologic diagnoses of mucinous cyst were qualified as showing lowgrade dysplasia in 12 (86%) cases and intermediate-grade dysplasia in 2 (14%) cases. Four cystic lesions were surgically resected after cytologic evaluation. The cytologic diagnosis of well-differentiated pancreatic (neuro)endocrine tumor, in 1 case, was confirmed after pancreaticoduodenectomy. Two mucinous cysts with cytologic diagnoses of low-grade dysplasia were resected and the diagnoses confirmed. One of these was a unilocular mucinous cystic neoplasm with low-grade dysplasia. The other proved to be an intraductal papillary mucinous neoplasm with low-grade to intermediate-grade dysplasia (Fig. 2) . A third case lacked mucinous epithelium in the aspirate and was interpreted to be most consistent with pseudocyst by cytology but mucinous by molecular analysis. It proved to be a largely denuded mucinous cystic neoplasm with low-grade dysplasia after distal pancreatectomy (Fig. 3) .
Results of Molecular Analysis
Six cystic lesions were classified as reactive or indolent on the basis of low DNA content and an absence of both KRAS mutation and LOH. One cyst displayed LOH at chromosome 3p with wild-type KRAS and was diagnosed as a serous cystadenoma. Seven cysts were classified as low-risk mucinous lesions due to detection of KRAS mutations. One of these had elevated CEA, and another showed LOH at 18q. One other case was classified as a mucinous cyst at risk for neoplastic progression due to the presence of a KRAS point mutation and a markedly elevated CEA level (458 ng/mL). Four cases were classified as nonmucinous cysts, and 1 was reported as neoplastic due to its high DNA content but was not further classifiable.
Correlation Between Cytologic and Molecular Evaluation
Cytologic and biomarker evaluations yielded concordant diagnoses in only 7 (35%) cases (Table 2) : cytologic assessment classified 2 cysts as mucinous with low-grade dysplasia and 2 cysts as mucinous with intermediategrade dysplasia, all 4 of which were diagnosed as low-risk mucinous cysts by Redpath Integrated Pathology Inc. One of these had a low CEA concentration ( < 0.5 ng/mL). One case was labeled a pseudocyst by cytology and classified as nonmucinous by Redpath Integrated Pathology Inc., and 1 cytology diagnosis correlated with the molecular diagnosis of serous cystadenoma. The (neuro)-endocrine tumor that was diagnosed by cytology and confirmed after resection was classified as a neoplasm, not otherwise specified, by Redpath Integrated Pathology Inc. (Fig. 1) . Discordant cases reflected difficulties in classification of mucinous cysts and their distinction from non-neoplastic cysts (pseudocysts). Four patients were rendered cytologic diagnoses of mucinous cyst with low-grade dysplasia but classified as reactive/indolent lesions by Redpath Integrated Pathology Inc. One patient had 3 metachronous cysts (5 mm in the body, 8 mm in the tail, and 9 mm in the tail) that were each cytologically diagnosed as mucinous cysts with low-grade dysplasia but reactive/indolent by the PathfinderTG assay (Table 2) . Fluid aspirated from the largest cyst in this case had an elevated CEA level of 6.5 ng/mL. All 3 cysts from that patient remained radiographically stable at 4, 11, and 17 months, at which time the 2 larger cysts were reaspirated and again cytologically classified as mucinous cysts with low-grade dysplasia. Two of these 4 cysts were surgically resected, one of which proved to be a mucinous cystic neoplasm with low-grade dysplasia, and the other was an intraductal papillary mucinous neoplasm with intermediate-grade dysplasia (Fig. 2) . The remaining patient had a 17-mm pancreatic neck cyst, unassociated with the pancreatic ducts, which was radiographically stable 2 years after diagnosis. Three other cysts were cytologically diagnosed as mucinous with lowgrade dysplasia but nonmucinous on the basis of the PathfinderTG assay. All 3 were clinically suspected to be mucinous in nature. One was a 34-mm cyst in the uncinate process that communicated with the main pancreatic duct and was unchanged at 6 months of follow-up. The second was a 50-mm cyst in the pancreatic head interpreted to be a branch duct intraductal papillary mucinous neoplasm. A third cyst in the pancreatic body measured 12 mm and communicated with the main pancreatic duct, which also showed segmental dilatation. This cyst was believed to represent a main duct intraductal papillary mucinous neoplasm.
Another case cytologically classified as a mucinous cyst with low-grade dysplasia was considered by Redpath Integrated Pathology Inc. to be at risk for neoplastic progression due to the detection of a KRAS point mutation and high DNA content. This pancreatic neck cyst spanned 15 mm and communicated with the main pancreatic duct. A repeat fine-needle aspiration at 3 months yielded mucinous epithelium with low-grade dysplasia. Finally, 3 cases were classified as pseudocysts by cytology and as low-risk mucinous cysts by biomarker analysis. One of these was a 23-mm cyst in the pancreatic body. It was considered to be mucinous by PathfinderTG analysis due to the presence of KRAS mutation and markedly elevated CEA (458 ng/mL). It remained radiographically stable for 6 months. Another patient had a 12-mm cyst that developed after multiple episodes of pancreatitis. The cyst aspirate contained acinar cells and proteinaceous material, but detection of a KRAS mutation without LOH led Redpath Integrated Pathology Inc. to make a diagnosis of a low-risk mucinous cyst. This patient had a repeat computed tomography scan 5 years later demonstrating an 8-mm cyst, which was not further evaluated. The last case was an 11-mm cyst in the pancreatic body that was unassociated with duct dilatation but developed in a patient with idiopathic pancreatitis. Molecular analysis revealed a KRAS mutation, and the CEA concentration was low (2.3 ng/mL), therefore the lesion was classified as a low-risk mucinous cyst at Redpath Integrated Pathology Inc. A subsequent distal pancreatic resection yielded a mucinous cystic neoplasm with lowgrade dysplasia (Fig. 3) . In summary, a cytologic diagnosis of mucinous cyst was rendered in 9 cases that were classified as reactive, indolent, or nonmucinous by the PathfinderTG assay, 2 of which were confirmed to be mucinous upon resection. Three cases were classified as pseudocysts by cytology and deemed mucinous by the PathfinderTG assay. Of these, only 1 was resected and proved to be mucinous. One cyst showed low-grade dysplastic cytologic features, but was considered at risk for neoplastic progression by PathfinderTG analysis. Only 33% of resected mucinous cysts were correctly classified by Redpath Integrated Pathology Inc.
DISCUSSION
Endoscopic ultrasound-guided fine-needle aspiration biopsy plays an important role in distinguishing between mucinous and nonmucinous pancreatic cysts and guiding management of patients with these lesions. Many factors limit the diagnostic potential of aspiration techniques, such as limited sample size and mucinous epithelial cell contaminants from the stomach or duodenum. There are also a variety of pitfalls, such as reactive epithelial cell changes that simulate neoplasia, that pose challenges to cytologists. For example, some malignant neoplasms, particularly (neuro)endocrine tumors, undergo cystic degeneration that mimic cystic neoplasms, whereas mucinous cysts may show extensive denudation and mimic pseudocysts. 12, 13 Serous cystadenomas with papillary projections simulate mucinous neoplasms in aspirate material. Congenital cysts also contain mucinous epithelium and masquerade as mucinous neoplasms, especially in young patients. 1, 7, 14, 15 These factors substantially impact the utility of cytology in the preoperative assessment of pancreatic cysts, and, in fact, the accuracy of cytology alone in distinguishing between mucinous and nonmucinous cysts ranges from 59% to 100%. [16] [17] [18] Mucinous cysts may be managed with conservative surveillance or surgical resection. Small ( < 3 cm), radiographically innocuous branch duct intraductal papillary mucinous neoplasms without mural nodules are typically observed unless other evidence indicates that they contain high-grade dysplasia or carcinoma. Thus, the value of any additional test, such as the PathfinderTG assay, is dependent on the degree to which it distinguishes between cysts that can be observed and those that require surgery. Ancillary tests that confirm the benign nature of larger cysts (> 3 cm) would also be of value.
Chemical analysis of cyst fluid contents is a useful adjunct to the clinical, radiologic, and cytopathologic evaluation of pancreatic cystic lesions. Cyst contents may be assessed for fluid viscosity, enzyme concentrations, and tumor markers. Fluid viscosity tends to be higher in mucinous cysts compared with nonmucinous cysts. Lewandrowski et al 19 evaluated 26 pancreatic cysts including 5 serous cystadenomas, 11 mucinous cysts, 1 pancreatic adenocarcinoma with cystic degeneration, and 9 pseudocysts. They compared cyst fluid viscosity with that of serum (relative viscosity = 1.4 to 1.8) and found serous cystadenomas and pseudocysts to have a mean relative viscosity of 1.24 (range, 1.05 to 1.47), whereas the relative viscosities of mucinous cysts ranged from 1.20 to >30 times that of serum. In that study, a threshold of 1.63 correctly classified all pseudocysts and serous cystadenomas as nonmucinous, but misclassified 1 mucinous cyst as nonmucinous. 19 Linder and colleagues subjected 23 pseudocysts, 13 serous cystadenomas, 21 mucinous cystic neoplasms, and 14 mucinous cysts with associated carcinoma to viscosity analysis. They found that benign and inflammatory cysts had a mean viscosity of 1.3 (range, 1.1 to 1.6) compared with mucinous cysts with low-grade to intermediate-grade dysplasia and high-grade dysplasia, which had mean viscosities of 1.8 (range, 1.6 to 1.9) and 1.9 (range, 1.6 to 2.3), respectively. 20 Differences in mean viscosities between nonmucinous and mucinous cysts were statistically significant in both studies.
Elevated amylase and lipase levels are typically seen in pseudocysts. In the previously cited study, Lewandrowski et al 19 found that amylase levels were elevated in 7 of 9 (78%) pseudocysts (range, 982 to 36,610 U/L) but were highly variable in mucinous cysts (range, 33 to 288,830 U/L) with substantial overlap between values among both groups. Lipase levels were also higher in pseudocysts (range, 62 to 6510 U/dL) but overlapped considerably with those of mucinous cysts (range, 7 to 4290 U/dL). 19 Linder et al 20 observed a general trend toward higher amylase and lipase levels in pseudocysts (mean, 7218 and 10,660 U/L, respectively) compared with mucinous cysts (mean, 1396 and 1796 U/L, respectively) with considerable overlap in enzyme level ranges between cyst groups. Thus, enzyme concentrations do not reliably discriminate between mucinous and nonmucinous cysts in all cases. Some biomarkers, including CEA, CA 19-9, and CA125, are higher in aspirates from mucinous cysts compared with those from nonmucinous cysts. Lewandrowski et al 19 found that a CEA cutoff value of 24.7 ng/mL was 100% sensitive and specific for the diagnosis of mucinous cysts and reliably excluded serous cystadenoma and pseudocyst. Others have found lower CEA cutoff values ( < 5 ng/mL) to show low sensitivity (50%) and high specificity (95%) for nonmucinous cysts, whereas a value >800 ng/mL is highly specific (98%) for mucinous lesions. 21 Thus, fluid aspirates from pancreatic cysts are commonly evaluated with a combination of cytology, pancreatic enzyme analysis, and assessment of CEA levels.
DNA from sloughed epithelium can be extracted from cyst contents and evaluated for molecular abnormalities that may also aid the classification of pancreatic cystic lesions. Activating KRAS mutations in codon 12 of exon 1 are common in both intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, and their frequency correlates with dysplasia severity in cyst epithelium. Low-level KRAS mutations are detected in mildly dysplastic mucinous epithelium but are more common in high-grade dysplasia and cancer, indicating that this alteration is an early event in pancreatic carcinogenesis. 22, 23 Homozygous mutations in DPC4 on 18q affect Smad4 production and occur in both intraductal papillary mucinous neoplasms and mucinous cystic neoplasms. 24, 25 Key tumor suppressor genes, such as the retinoblastoma-interacting zinc finger (RIZ) on 1p36, VHL on 3p25-3p26, and APC on 5q23, show LOH that is detectable in brush cytology specimens of pancreatic and bile duct cancers. 26 Other common molecular deviations described in pancreatic ductal adenocarcinoma include mutations of MTS-1 on 9p2, TP53 on 17p, and aberrant expression of the patched gene (PTCH) on 9q22. 22, 27, 28 Presumably, some of these biomarkers may be altered in mucinous cysts with intermediate-grade to high-grade dysplasia and thus, could be used to identify those at risk for cancer development.
Molecular testing of cytology samples from pancreatic cysts is of limited value for several reasons. Although LOH in RIZ, VHL, and APC correlates with malignancy and discriminates between benign and malignant cells in bile duct brushings, these genes are not altered in all mucinous cysts, especially those with lowgrade dysplasia, and thus they have no application in the evaluation of incidentally discovered pancreatic cysts. 10 Cyst fluid classification on the basis of fluid analysis for KRAS mutations leads to false-positive and false-negative results. Non-neoplastic pancreatic tissues may harbor KRAS mutations and result in misclassification of pseudocysts as mucinous cysts. 29 Indeed, 2 cases in our study were thought to clinically and cytologically represent pseudocysts but harbored KRAS mutations, resulting in a molecular classification of mucinous cysts. Conversely, recent data also suggest that most DNA from cyst contents is derived from nonlesional cells. 30 Therefore, classification on the basis of LOH may fail to detect mucinous cysts. Finally, whole exome sequencing demonstrates that several markers included in the PathfinderTG assay are not even altered in pancreatic mucinous cysts. Their value in discriminating between mucinous and nonmucinous cysts has never been independently evaluated. 31 Khalid et al 32 analyzed 113 pancreatic cysts, including 40 mucinous cysts with high-grade dysplasia or associated invasive carcinoma, 48 mucinous cysts with low-grade to intermediate-grade dysplasia, and 25 nonmucinous cysts. They found that DNA quantity and quality, presence of KRAS mutations, and LOH as assessed by the PathfinderTG assay were statistically associated with the presence of malignancy, whereas cytology preparations were diagnostic in only 30 (75%) cysts with high-grade dysplasia or invasive carcinoma. Unfortunately, although the authors of that study correlated data points from the PathfinderTG assay with final pathologic diagnoses, they did not provide information regarding the final classification offered by Redpath Pathology Laboratory Inc. Thus, it is not clear from this study whether molecular classification of pancreatic cysts is superior to cytologic assessment.
Shen et al 33 analyzed 35 pancreatic cyst fluids for CEA levels, DNA content, KRAS mutations, and LOH using the PathfinderTG assay and correlated their results with clinical diagnoses. In that study, cysts were clinically classified as: malignant (6 cases) if they contained highgrade dysplasia or invasive carcinoma; benign, mucinous (16 cases) if they showed low-grade to intermediate-grade dysplasia; and benign, nonmucinous (14 cases), using a combination of radiographic features, quality of aspirated cyst contents (mucoid vs. watery), cyst fluid CEA levels, and cytologic or histologic findings, when available. The molecular diagnoses were concordant with the clinical classification in 31 (89%) cases, including 83%, 87%, and 93% of malignant, benign mucinous, and benign nonmucinous cysts, respectively. These findings are clearly superior to the 39% agreement between molecular and cytologic classification reported herein. However, the cases included in that study were substantially different from our cases. Most of the cysts described by Shen and colleagues were large, clinically symptomatic tumors that met the criteria for surgical resection. Six contained high-grade dysplastic epithelium, at least 3 of which were associated with invasive adenocarcinoma and showed radiographic features suspicious for carcinoma. The added value of the PathfinderTG assay in such cases is limited, as most should be resected if possible, regardless of the results of ancillary tests.
Molecular testing for LOH and KRAS mutations in cyst aspirates is less helpful when clinical and pathologic features of overt malignancy are lacking. Khalid and colleagues used the PathfinderTG assay to evaluate aspirates from 36 pancreatic cysts, including pseudocysts (6), serous cystadenoma (1), lymphoepithelial cyst (1), retention cyst (1), mesothelial cyst (1), and mucinous cysts (26) . Fifteen of the latter contained epithelium with lowgrade to intermediate-grade dysplasia, and 11 had highgrade dysplasia or invasive carcinoma. 11 The authors found that nonmucinous cysts lacked LOH and KRAS mutations in all cases and suggested that LOH and KRAS status aid in distinguishing between mucinous and nonmucinous cysts. It should be noted, however, that only 6/15 (40%) of their mucinous cysts with low-grade or intermediate-grade dysplasia had detectable KRAS mutations, and one of their cases with high-grade dysplasia lacked any abnormality by PathfinderTG analysis. The results of our study are similar. We also observed suboptimal (< 50%) agreement between the cytologic and molecular classification offered by Redpath Integrated Pathology Inc. Ten of 14 (71%) cysts classified as mucinous by cytology were considered to be nonmucinous by Redpath Integrated Pathology Inc., including 2 cases that were surgically resected [mucinous cystic neoplasm (1 case) and intraductal papillary mucinous neoplasm (1 case)]. Three cases considered likely pseudocysts by cytology and clinical evidence were classified as low-risk mucinous cysts owing to detection of KRAS mutations.
Only 1 other study has evaluated the utility of the PathfinderTG assay when classifying small, incidentally detected pancreatic cysts. Toll et al 34 subjected 63 small (< 3 cm) pancreatic cysts to cytologic evaluation, CEA concentration analysis, and the PathfinderTG assay. Cytologic smears were classified as unsatisfactory, benign nonmucinous, mucinous, or malignant. The authors reported 56% concordance between cytologic and molecular diagnoses and found that they were able to render molecular diagnoses in 16 cases deemed unsatisfactory for cytologic assessment. The authors concluded that molecular analysis enhances the diagnostic yield of cyst aspirates when only limited material is available.
An important shortcoming of this study is the lack of surgical follow-up and definitive cyst classification based on review of resection specimens. One could certainly question the validity of our cytologic classification given the absence of a "gold standard." However, current trends in the management of small, uncomplicated pancreatic cysts are prohibitive in this regard. Most innocuous cysts are not surgically resected, and thus cytologic diagnoses are solely supported by subsequent surveillance imaging, repetitive aspiration, and clinical outcome. These parameters, as detailed in the current study, suggest that our cytologic assessment of pancreatic cysts was largely accurate. Four cysts were reaspirated and assessed by cytology that confirmed the original cytologic diagnoses. Surgical resection verified the cytologic diagnoses in all but one case, which was a largely denuded mucinous cystic neoplasm.
In summary, proponents of the PathfinderTG assay suggest that it distinguishes mucinous from nonmucinous cysts, especially if cytology aspirates are scant. However, most of their data are based on assessment of pancreatic cysts that show clinical features, such as large size, multiloculation, mural nodules, or high-grade dysplasia, any one of which should prompt surgical resection. Results from these studies do not necessarily imply that the PathfinderTG assay is useful when applied to smaller, or uncomplicated, cysts that qualify for clinical surveillance. Redpath Integrated Pathology Inc. misclassifies approximately 50% of cyst aspirates on the basis of the PathfinderTG assay. We conclude that commercial laboratory reports, such as those of Redpath Integrated Pathology Inc., should refrain from supplying pathologic diagnoses and management recommendations to clients until better biomarker panels are available.
